Loading stock data…
$46.75-0.39 (-0.83%)
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
Rigel Pharmaceuticals, Inc. in the Healthcare sector is trading at $46.75 with a market capitalization of $909M. Wall Street consensus targets $63.00 (5 analysts), implying a +34.8% move over the next 12 months. The stock is currently 11% below its 52-week high of $52.24, remaining 27.3% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $78.70M↑ | $58.82M↓ | $69.80M↑ | $69.46M↓ | $101.69M |
| Gross Profit | $70.18M↑ | $54.21M↓ | $63.85M↓ | $64.71M↓ | $97.18M |
| Operating Income | $23.57M↑ | $11.88M↓ | $23.17M↓ | $28.42M↓ | $61.10M |
| Net Income | $17.29M↑ | $8.65M↓ | $268.06M↑ | $27.90M↓ | $59.61M |
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibito...